

Press release

Lund, 6th November, 2023
EQL Pharma AB (publ)
556713-3425

EQL PHARMA

Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24

EQL Pharma AB (publ) will publish its quarterly report for the second quarter, 2023/24, on Friday, November 17th, before stock markets opening.

At 10.00 (CET) 17th November, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate.

Use the following link to access the virtual meeting: <https://tinyurl.com/mpzed7uf>

Date and time

November 17th, 2023, at 10.00 (CET) the presentation starts. Time required for presentation and subsequent question time is estimated at a maximum 1 hour.

Make sure you are able to attend the video conference by logging in shortly before the start of the conference.

For further information, please contact:

Axel Schörling

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 25 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.